Wednesday, June 07, 2006

Licensing Sales Reps: Is It a Bad Idea?

An amendment to the proposed Massachusetts State Budget -- recently approved by the State Senate -- could make the state the first in the nation to license pharmaceutical sales reps (see SECTION 100NN) and prohibit them from providing entertainment, gifts, payments or travel to doctors, healthcare facilities or public officials (see SECTION 44L), The Boston Globe reports (see "Senate OK's licensing of drug reps").

SECTION 44L, which was tacked on to the budget by Senator Mark Montigny, Democrat of New Bedford -- the same senator who introduced
Senate Bill #402, which also attempted to limit gifts to physicians -- states: "No pharmaceutical manufacturer agent shall knowingly and willfully offer or give to a physician or a member of a physician'’s immediate family, and no physician shall knowingly and willfully solicit or accept from any pharmaceutical manufacturer, gifts of any value at any time."

This is actually more onerous than SB #402, which would require physicians (and other healthcare officials) in the state to file a "gratuity disclosure statement" listing "any gifts aggregating more than $100 in the two preceding calendar years." That bill did not "ban" gifts and did not even set limits on gifts as far as I can see. The state, however, could engage in the "prosecution of illegal conduct involving gifts, educational or research grants, or other economic benefits provided by a pharmaceutical company or an agent of a pharmaceutical company to a public charity [ie, hospital] the circumstances of which reasonably call into question whether such funds are being put to a charitable purpose or indicate a breach of the public trust in the administration of a public charity." This did not include doctors (they are not charities).

Anyway, my main interest is SECTION 100NN regarding licensing pharmaceutical reps.

[If you want to learn more about pharma gifts to physicians, please see a previous Pharma Marketing Blog post on the topic: "Gifts That Keep on Giving" or consider ordering the following Pharma Marketing News reprint: "Free Gifts to Physicians: What's the Big Deal?"]
Is it a bad idea to require pharma sales reps to be licensed?

Why pharma sales reps and not GE light bulb sales people? I don't know. Maybe states require other types of sales people to be licensed. I haven't heard of it, though.

You could say that pharma reps are different -- they sell a product that affects the health of the citizens of a state. Senator Montigny obviously concurs:

"Hairdressers and manicurists must be licensed to work in the Commonwealth," Montigny said. "Pharmaceutical representatives who market prescription drugs and attempt to influence doctors to prescribe name-brand drugs should also be licensed."
But if licensing meant better trained sales reps, then I would favor it. SECTION 100NN does have provision for training as part of the licensing process:
"As a prerequisite to licensing, pharmaceutical representatives shall complete such training as may be deemed appropriate by the department departmentt of public health, in consultation with the board of registration of pharmacy]. As a prerequisite to the renewal of a pharmaceutical representative license, the licensee shall complete continuing education as may be deemed appropriate by the department."
Not only would this open up a new business for training companies, but it could actually make drug reps more effective, depending on the training provided. I assume, for example, that one goal of the training would be to raise the rep's knowledge of the therapy category and competing treatments -- especially generics.

From the experience of people familiar with the preparedness of reps, there are some gaps. Here's an assessment by Michael Kessler, MD, VP of Metamorph Doctors, LLC, a sales rep assessment company:

"Representatives, in general, are scoring lower in their ability to communicate clinical information in a way that is palatable and understandable to the doctor." (As reported in Pharma Marketing News: "Sales Rep Assessment: Shoot the Messenger, the Message, or Both?")
Perhaps doctors are more demanding these days and despite efforts to standardize assessments, they are less forgiving in judging this skill. Nevertheless, this decline in an important indicator is a worrisome trend in light of recent commitments by the pharmaceutical industry to ensure that doctors become more knowledgeable about new drugs, especially before DTC campaigns are launched.
"We also see an across-the-board lack of knowledge of competitors' products or the lack of ability to speak about competitors'’ products in a comparative way," says Kessler. [op cit]
Even sales reps themselves agree that their training levels are inappropriate. According to a G & S survey of pharma sales reps -- see more on this survey in the post "Industry PR & Rep Morale" -- three quarters of respondents agreed that they need more training. 36% felt a need for more disease state training in particular.

Reps also are not very knowledgeable about DTC campaigns relating to their products and their competitors' products: only 40% were very or extremely informed about their products' DTC campaigns and only 10% were that knowledgeable about the competitors' DTC campaigns.

I don't really believe state-mandated training and licensing is the answer to this problem. The effort in Massachusetts, however, represents another exploitation of a chink in pharma's armor that critics are exploiting to pass laws that limit pharmaceutical marketing.

Perhaps the industry has been too busy building their army of reps to properly train them in battlefield conduct and arm them with the knowledge they need to be true "trusted colleagues" of their physician clients.

SFE Supplement CoverIncrease Physician Access and Detailing Effectiveness

Through articles and real-world case studies this Special Supplement presents the collective wisdom of many marketing experts who offer solutions to the problem of decreasing sales rep effectiveness and decreasing return on the physician marketing dollar.

The information in this Special Supplement is certain to give you a better understanding of the issues relating to physician access and how to improve the effectiveness of your physician marketing and sales campaigns.

Order and pay for this Special Supplement now using your credit card.

ONLY $19.95 - SAVE $10!
PDF file delivered to you by email (usually within minutes of placing your order).


  • A Crisis in Professional Detailing... pg. 2
  • Marketing's Role in Limiting Physician Access... pg. 4
  • Finding the "Right Stuff" to Revitalize Sales Productivity... pg. 6
  • Facilitating Physician Access and Education Through Online Conferencing... pg. 7
  • The Targeted Model... pg. 9
  • Limbic Market Research... pg. 11
  • Intelligent Online Sampling Strategies... pg. 13
  • Increase Prescription Sales with Smart Tools at the Point of Care... pg. 16
  • A Novel Approach to Communicating with Physicians... pg. 18
  • Increase Sales Representative Performance and Productivity by Building Collaborative Physician Relationships... pg. 20
  • Promoting Pull Through Prescriptions via Value-Added Free Medical Practice Web Sites and Patient Education... pg. 21
  • Gauging Physician Behavior and CE Impact with Two-Way, Real Time, Web-Based Technology... pg. 22
  • Live, Online, Interactive Conference with Experts to Provide Detailed Product Information to Physicians... pg. 23
  • Audio with Synchronized Visuals Streaming Over Low Bandwidth Internet Connections for Physician Detailing... pg. 24
  • Online Content Management System for Sales and Marketing Representatives... pg. 25
  • Percentage of Physicians Indicating Sales Rep Attribute is Valuable
  • US promotional Spending by Pharma Breakout
  • Impact of Sampling on Physician Prescribing
  • Pharmaceutical Marketing Influence on Physician Prescribing
  • Percent of Physicians Rating Information Services Good or Excellent (Internet, Reps, Journals, Symposia)
  • PDR Subscriber Survey
  • MD Consult Survey
  • Sources for Learning Prescribing Information


  1. Licensing is totally useless. The problem isn't to control and monitor who sells drugs, but how they do it. Legislators should instead use their time and power to promote a more ethical way of doing pharmaceutical business, i.e. banning gifts to doctors and such perks. It isn't because a medical professional have an a high degree of eduction that they cannot be misleaded in their therapeutic choices by ''meetings'' in Hawai and such ''bribes''.

    My marketing blog:

  2. Anonymous2:52 PM

    If sales reps appear to have less information about competing drugs it is because the FDA prohibits comparative statements unless there have been two head to head trials.
    Head to head trials are rarely done, not because of what most folks think-would not want to loose in the trial- but because FDA will NOT consider those types of trials for drug approval. Companies would rather spend their money on trials that will assist in getting the drug approved.


Related Posts Plugin for WordPress, Blogger...